Nature calls for permanent international oversight of brain organoid research in an editorial prompted by its own publication on transplanting human tissue into mice

Nature calls for permanent international oversight of brain organoid research in an editorial prompted by its own publication on transplanting human tissue into mice

On September 29, Nature responded with an editorial to a study it had itself published on transplanting brain organoids into mice, noting that work on a permanent oversight mechanism is already under way. The editorial draws on a programmatic paper in Science from 2025 and on the report of a conference held in Asilomar that November, published in early September 2026.

On September 16, Nature published work from Sergiu Pașca's laboratory at Stanford University: in newborn mice whose cortex had been artificially reduced in size, transplanted human tissue (organoids, three-dimensional fragments of developing cortex grown from stem cells) occupied on average 91.9% of cortical volume and connected to the animal's neural pathways. The authors noted that more mature tissue and earlier transplantation timepoints call for separate ethical guidelines. The editorial describes the result as a turning point and immediately raises a question that had previously remained theoretical: whether animals carrying implanted human tissue might acquire human-like properties of consciousness or cognition, and how one would even measure that. From this question the editorial derives its position: the field needs a permanent international oversight mechanism.

Nature identifies an unresolved question: who will take on this oversight. Scientific academies and professional societies carry authority but are typically confined to a single discipline, while organoid research demands the involvement of the social sciences and the humanities from the outset. As a working example, the editorial describes Stanford's practice in the Pașca experiment: an independent advisory group composed of scientists, social scientists, humanists, and patient-organization representatives accompanied the project at every stage, reviewed protocols, and proposed amendments.

Pașca and Stanford law professor Hank Greely have been advocating for such a mechanism since 2018, when they first called for ethical guidelines for organoids in the same journal. In 2025, together with 15 co-authors, they articulated the case in Science: an ongoing international process is needed. That November, they convened more than 70 scientists, ethicists, and patient-organization representatives at Asilomar, the same site as the 1975 conference on managing the risks of genetic engineering.

The conference report appeared in early September. Participants rejected outright bans as a risk of stifling promising treatments for neurological diseases and proposed a decentralized, continuously updated process: monitoring new publications, providing regular ethics training for institutional review committees, and maintaining an open dialogue with the public.

"People need concrete recommendations on the pressing questions they face in the lab, on institutional ethics committees, and in patient organizations," Greely says.

Pașca states the boundary of the field directly:

"This research raises important ethical questions that the scientific community cannot and should not answer alone."

Nature draws a direct parallel with genetically modified food: that field went through major public conflicts precisely because scientists moved faster than they consulted with society.

The agreement so far covers direction and principles: a decentralized process involving scientists, journals, funders, and patient organizations, with no single prohibitory authority. Who will lead the process and how it will be funded is to be determined through a multiyear plan with initial pilot procedures.